semaglutide fda indications FDA-Approved Dosages and for GLP-1 and Dual GIP/GLP-1 FDA Approves Oral Semaglutide as

10.14740/jocmr2820w 15

doi:10.1073/pnas.1733391100

Same-day prescriptions Local pharmacy pick-up Hassle-free Rx refills Tirzepatide is the active ingredient in FDA-approved injectables for both weight loss (Zepbound) and type 2 diabetes (Mounjaro)

Pre-restart assessment should include: Review of the reason for discontinuation and whether it has been adequately addressed Current weight and glycemic status (if diabetic) Assessment of gastrointestinal symptoms and any contraindications Medication reconciliation to identify potential drug interactions For patients taking insulin or sulfonylureas, consider dose reductions to prevent hypoglycemia For women of childbearing potential using oral contraceptives, recommend backup contraception for 4 weeks after restarting and after each dose increase Discussion of realistic expectations and commitment to continued treatment Patient counseling is essential